实用肿瘤杂志2025，Vol.40Issue(6)：499-510,12.DOI:10.13267/j.cnki.syzlzz.2025.073
食管鳞癌免疫治疗用于新辅助治疗浙江省专家共识(2025版)
Expert consensus on immunoneoadjuvant therapy for esophageal squamous cell carcinoma in Zhejiang province(2025 edition)
摘要
Abstract
China exhibits a notably high incidence of esophageal cancer,with the annual numbers of new cases and deaths constituting approximately half of the global total.Notably,over 90%of esophageal cancer cases in China are classified as squamous cell carcinoma.Despite advancements in surgical techniques,radiotherapy,chemotherapy,and other therapeutic modalities,the survival rate of patients with esophageal squamous cell carcinoma has not shown a significant improvement over the past few decades.Currently,neoadjuvant chemoradiotherapy remains the standard treatment for patients with locally advanced esophageal squamous cell carcinoma,while immu-noneoadjuvant therapy is still under investigation.Among patients with locally advanced esophageal squamous cell carcinoma who receive immunoneoadjuvant therapy,some are enrolled in exploratory clinical studies,whereas others receive treatments that fall outside the scope of clinical research.Consequently,the Esophageal Cancer Specialized Committee of the Zhejiang Anti-Cancer Association initiated the formation of an expert working group under the leadership of the Second Affiliated Hospital of Zhejiang University School of Medicine.This consensus was developed through a multidisciplinary collaboration that encompassed fields such as thoracic surgery,medical oncology,and radiotherapy.It integrates the latest relevant literature from both domestic and international sources with the clinical realities in China.The objective is to offer comprehensive,multi-dimensional,and precise guidance for immunoneoadjuvant therapy in patients with locally advanced esophageal squamous cell carcinoma,thereby assisting physicians in mitigating potential risks and enhancing clinical deci-sion-making.关键词
食管鳞癌/免疫检查点抑制剂/新辅助治疗Key words
esophageal squamous cell carcinoma/immune checkpoint inhibitors/neoadjuvant therapy引用本文复制引用
浙江省抗癌协会食管癌专委会,沈虹,吴明..食管鳞癌免疫治疗用于新辅助治疗浙江省专家共识(2025版)[J].实用肿瘤杂志,2025,40(6):499-510,12.基金项目
浙江省重点研发项目(领雁计划攻关项目)(2023C03064) （领雁计划攻关项目）
科技部国家重点研发项目(2023YFF1204404) （2023YFF1204404）
